• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support –
            • North & South America –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management –
            • Study Start-up & Feasibility –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management –
            • Patient Recruitment –
            • Personalized Clinical Trial Operations –
            • Biometrics –
            • Medical & Safety Monitoring –
            • Clinical Data Management –
            • Medical Writing –
        • Clinical Development Strategy –
            • Clinical Development Planning –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies –
            • Cell & Gene Therapy Strategies –
            • CDx Regulatory and Market Access –
        • Clinical Trial Design –
            • Basket & Umbrella Trials –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials –
            • Master Protocol Trials –
            • Decentralized Clinical Trials
        • Biostatistics –
            • Statistical Consulting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design –
            • Data Monitoring Committees –
            • CDISC Programming and Documentation –
            • eCTD Submissions –
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Specialty Lab Services Overview –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization –
        • Immune Monitoring –
            • Immune Monitoring by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID –
            • Cytokine Profiling –
            • Gene Expression Profiling –
            • ELISpot and FluoroSpot –
            • Custom Assays –
        • Flow Cytometry –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • Genomics –
            • NanoString Assays –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR –
            • qPCR –
            • NGS –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
        • Tissue & Liquid Biopsy –
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry –
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services –
            • NanoString Assays
        • Bioanalytical Testing –
            • Immunogenicity Testing –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays –
            • ADA Assays –
            • MesoScale Discovery (MSD) Assays –
            • Quanterix SIMOA –
            • ELISA
        • Cytokine Analysis –
            • ELISA –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex –
            • Quanterix SIMOA
        • Preclinical Target and Biomarker Validation –
            • Cell Based Assays –
            • Target Expression – XpressWay Profiles –
            • Tissue Cross-Reactivity –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • Computational BiologyImage

                Computational Biology


                Domain experts from our QuartzBio team utilize integrated and harmonized data and tailored AI solutions to drive preclinical and clinical development, including patient stratification, signature development, predictive modeling of drug response, and MOA characterization.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio –
            • Biomarker Data Management –
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • Virtual Sample Inventory Management –
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Companion Diagnostics
    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
        • By Research Phase
        • Preclinical Development –
        • Early Phase Trials (I-IIa) –
        • Late Phase Trials (IIb-III) –
    • News &
      Insights
        • Blog –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources –
        • Thought Leadership –
        • News –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People –
        • Careers
        • Regulatory Information –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    • Home
    • COVID-19 Home Testing: Looking Back at the Journey to Authorization
    Blog Clinical Research Insights Translational & Lab Insights
    Article

    COVID-19 Home Testing: Looking Back at the Journey to Authorization

    Written By Jo-Ann Fabila Gonzales • June 7, 2022 • 5 min. read

    The journey to bring at-home COVID-19 diagnostics to the market

    The public health emergency caused by the SARS-CoV-2 outbreak precipitated a significant upheaval for industries around the world. Pivotal stakeholders dedicated to the health and safety of the global population worked diligently to find solutions to tackle the novel COVID-19 virus and its effects. Global health organizations collaborated with healthcare experts to develop a range of diagnostic solutions and treatments that were regulated, effective, and usable for widespread applications.

    Responding to a surge in early COVID-19 infections

    In late 2019, SARS-CoV-2 began to spread, traversing the world with breakneck speed, and causing staggering infection rates.1 Governing bodies, healthcare professionals, manufacturers, and other stakeholders searched for solutions to this global health and safety risk.

    Healthcare professionals (HCPs) and frontline workers leaned on personal protective equipment (PPE) to slow and reduce the spread of infections; however, the meteoric increase in resource demand was unprecedented, and the international supply chain could not immediately meet the rising needs. The global infrastructure was under extreme pressure, driving diagnostic developers to bring COVID-19 testing solutions, processes, and devices to the market.

    The initial need was to determine how best to detect a COVID-19 infection in an individual. Tests fell into three broad categories2:

    • Tests to diagnose, including molecular and antigen tests, which detect viral fragments.
    • Test to detect immune responses which look for the presence of SARS-CoV-2 antibodies.
    • Viral load testing to inform patient management for those with confirmed cases.

    Bringing COVID-19 diagnostics to market

    To commercialize diagnostic tests in the United States, developers were required to adhere to the FDA’s emergency use authorization (EUA) policy. EUAs permit the FDA to facilitate access to unapproved medical products or unapproved uses of approved medical products in public health emergencies. The EUA policy and framework had originally been finalized in January 2017, and the new COVID-19 circumstances required substantial revisions to accommodate the quickly evolving pandemic and enable rapid life-saving actions.3

    Due to the rising infection and mortality rates, resource strains, and economic burden, diagnostic testing solutions were needed in both healthcare settings and for use in the home

    The FDA initially prioritized laboratory-based tests and point-of-care (PoC) tests, to better inform decision-making. At-home testing—both prescription and over the counter (OTC) tests which relied on self-collection and self-testing—were integral in mitigating the spread of disease.4–6

    The FDA’s initial response and desire to bring at-home testing to the market caused an unintended flood of unverified claims, falsified data, and illegitimate tests to be distributed to the public.7,8 As a result, hundreds of products were pulled, and more than 60 warning letters (as of March 2022) were issued.9 Additional considerations and reviews were required for authorization of home-based diagnostics due to the range of potential risks and issues that could arise10:

    • The safety and stability of the transport media components;
    • Determining how well typical users can safely and successfully collect specimens at home;
    • Ensuring proper shipment and stability of specimens collected at home and sent for analysis;
    • Verifying how well typical users can handle fully at-home tests, including safely and successfully collecting specimens, administering the test, and interpreting the results accurately.

    To help diagnostic developers navigate the EUA process, templates for preparation, submission, and authorization have been made available, on the heels of The New England Journal of Medicine citing, “the importance of authorizing medical products independently, of the basis of sound science, and not permitting market entry of tests without authorization.”10–12 The article then goes on to highlight the fruitful collaboration opportunities for public-private research, allowing accurate tests with independent assessment of assays to be available to the public.

    Successful study, authorization, and market-entry of home-based COVID-19 tests

    By ensuring all stages and actions were completed in accordance with FDA guidelines and/or EUA requirements, diagnostic developers overcame the testing and regulatory challenges, from preclinical stages to study design and testing and through submission and filing.

    Efficient clinical trial design was a key driver of these authorizations, factoring in medical and stakeholder needs while simultaneously building evidence-development strategies to provide a solid foundation for market accessibility.

    Precision helped to bring many EUAs to market with diagnostic development support, innovative technologies, and a significant inventory of biospecimens that continue to support COVID-19 assay development programs.

    • To help usher in the next phase of testing, Precision is supporting a seamless shift from EUA to 510(k) for COVID-19 assays.
    • To read more about our accelerated vaccine, therapeutic and diagnostic development capabilities, visit the COVID-19 Resource Center.

    References:

    1. World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov. Accessed 7 June 2022.

    2. Food and Drug Administration. In vitro diagnostics EUAs. https://www.fda.gov/medicaldevices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medicaldevices/vitro-diagnostics-euas. Last updated 17 March 2021. Accessed 7 June 2022.

    3. Food and Drug Administration. Emergency use authorization of medical products and related authorities: Guidance for industry and other stakeholders. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities. Last updated 17 October 2018. Accessed 7 June 2022.

    4. Centers for Disease Control and Prevention. Guidance for SARS-CoV-2 point-of-care and rapid testing. https://www.cdc.gov/coronavirus/2019-ncov/lab/point-of-caretesting.html. Last updated 19 January 2022. Accessed 7 June 2022.

    5. Shuren JE. Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues authorization for Quidel QuickVue at-home COVID-19 test. https://www.fda.gov/newsevents/press-announcements/coronavirus-covid-19-update-fda-issues-authorizationquidel-quickvue-home-covid-19-test. Published 1 March 2021. Accessed 7 June 2022.

    6. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first COVID-19 test for self-testing at home. https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-selftesting-home. Published 17 November 2020. Accessed 7 June 2022.

    7. Hale C. FDA leaders recount flaws in 2020’s open-door policy for COVID-19 antibody tests. https://www.fiercebiotech.com/medtech/fda-leaders-recount-flaws-2020-s-opendoor-policy-for-covid-19-antibody-tests. Published 16 February 2021. Accessed 7 June 2022.

    8. Food and Drug Administration. Template for manufacturers of molecular and antigen diagnostic COVID-19 tests for non-laboratory use. https://www.fda.gov/media/140615/download. Published 29 July 2020. Accessed 7 June 2022.

    9. Food and Drug Administration Warning Letters. https://www.fda.gov/inspectionscompliance-enforcement-and-criminal-investigations/compliance-actions-andactivities/warning-letters. Current as of 7 June 2022. Accessed 7 June 2022.

    10. Food and Drug Administration. Policy for coronavirus disease-2019 tests during the public health emergency (revised). https://www.fda.gov/regulatory-information/searchfda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-healthemergency-revised. Accessed 7 June 2022.

    11. Food and Drug Administration. Emergency use authorization. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-use-authorization#covidinvitrodev. Current as of 7 June 2022. Accessed 25 March 2022.

    12. Shuren J, Stenzel T. The FDA’s experience with Covid-19 antibody tests. https://www.nejm.org/doi/10.1056/NEJMp2033687. Published online 18 February 2021. Accessed 8 March 2022.


    • Jo-Ann Fabila Gonzales

      Jo-ann Fabia Gonzales is an experienced regulatory affair professional with more than 20 years of experience in biotechnology. Her career has a rich focus on medical devices and IVD regulatory support.

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR